Latest News

STAT Plus: Pharma donates big bucks to U.K. patient groups, but transparency found lacking

Over a recent four-year period, drug makers contributed more than $72 million to hundreds of United Kingdom patient advocacy groups that lobby and facilitate research into new treatments, and the payments often reflected the commercial priorities of companies making the donations, a new study finds.

Yet transparency about the payments is often lacking, the authors found, underscoring concerns that the pharmaceutical industry may be co-opting patient groups, which frequently work with U.K. agencies to ensure medicines are paid for by the government. As an example, the authors pointed to the National Institute for Health and Care Excellence, which runs cost effectiveness appraisals.

Continue to STAT Plus to read the full story…

Source link

Related posts

In cost transparency move, Trump admin could require disclosure of negotiated rates between insurers and hospitals


Drinking contexts associated with early onset of alcohol intoxication among adolescents


Medical News Today: What is asthma?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy